Cancer Biotherapy and Radiopharmaceuticals最新文献_第8页

Enhanced Tumor Targeting of Radiolabeled Mouse/Human Chimeric Anti-Tn Antibody in Losartan-Treated Mice Bearing Tn-Expressing Lung Tumors. 放射性标记的小鼠/人嵌合抗 Tn 抗体在洛沙坦治疗的携带 Tn 表达肺肿瘤的小鼠中增强了肿瘤靶向性

IF 2.4 4区医学

Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-06-01 Epub Date: 2024-01-12 DOI: 10.1089/cbr.2023.0138

Marcos Tassano, Ximena Camacho, Teresa Freire, Carolina Perroni, Valeria da Costa, Mirel Cabrera, Maria Fernanda García, Marcelo Fernandez, Juan Pablo Gambini, Pablo Cabral, Eduardo Osinaga

{"title":"Enhanced Tumor Targeting of Radiolabeled Mouse/Human Chimeric Anti-Tn Antibody in Losartan-Treated Mice Bearing Tn-Expressing Lung Tumors.","authors":"Marcos Tassano, Ximena Camacho, Teresa Freire, Carolina Perroni, Valeria da Costa, Mirel Cabrera, Maria Fernanda García, Marcelo Fernandez, Juan Pablo Gambini, Pablo Cabral, Eduardo Osinaga","doi":"10.1089/cbr.2023.0138","DOIUrl":"10.1089/cbr.2023.0138","url":null,"abstract":"Aim: ChiTn, a mouse/human chimeric anti-Tn monoclonal antibody, was radiolabeled with iodine-131 (131I) and technetium-99m (99mTc) to assess its biodistribution and internalization in Tn-expressing (Tn+) and wild-type (Tn-) LL/2 lung cancer cells. Results: Selective accumulation and gradual internalization of ChiTn were observed in Tn+ cells. Biodistribution in mice with both Tn+ or Tn- lung tumors indicated that the uptake of radiolabeled ChiTn within tumors increased over time. Dual-labeling experiments with 99mTc and 131I showed different biodistribution patterns, with 99mTc exhibiting higher values in the liver, spleen, and kidneys, while 131I showed higher uptake in the thyroid and stomach. However, tumor uptake did not significantly differ between Tn+ and Tn- tumors. To improve tumor targeting, Losartan, an antihypertensive drug known to enhance tumor perfusion and drug delivery, was investigated. Biodistribution studies in Losartan-treated mice revealed significantly higher radiolabeled ChiTn uptake in Tn+ tumors. No significant changes were observed in the uptake of the control molecule IgG-HYNIC™99mTc. Conclusions: These findings demonstrate the enhanced tumor targeting of radiolabeled ChiTn in Losartan-treated mice with Tn-expressing lung tumors. They highlight the potential of ChiTn as a theranostic agent for cancer treatment and emphasize the importance of Losartan as an adjunctive treatment to improve tumor perfusion and drug delivery.","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"337-348"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139433111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Theranostic Innovation by Humane N-of-One Cancer Care in Real-World Patients. 通过对现实世界中的癌症患者进行人性化的 "N-of-One "癌症护理，实现 Theranostic 创新。

IF 2.4 4区医学

Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-06-01 Epub Date: 2024-02-07 DOI: 10.1089/cbr.2023.0198

J Harvey Turner

{"title":"Theranostic Innovation by Humane N-of-One Cancer Care in Real-World Patients.","authors":"J Harvey Turner","doi":"10.1089/cbr.2023.0198","DOIUrl":"10.1089/cbr.2023.0198","url":null,"abstract":"Patients with relapsed or refractory metastatic cancer unresponsive to standard therapies have motivated nuclear physicians to develop innovative radioligands, precisely targeted to tumor molecular receptors, for effective treatment of specific advanced malignancies. Individual practitioners in departments of nuclear medicine across the world have performed first-in-human studies on compassionate patient usage N-of-One protocols. These physician-sponsored studies then evolved into early-phase clinical trials and obtained real-world data to demonstrate real-world evidence of effectiveness in prolonging survival and enhancing quality of life of many so-called \"End-Stage\" cancer patients. Virtually all the therapeutic radiopharmaceuticals in current clinical oncology have been discovered and developed into effective specific treatments of targetable cancers by individual doctors in the course of their hospital practice. Pharma industry was not involved until many years later when performance of mandated Phase 3 randomized controlled trials became necessary to achieve regulatory agency approval. This article traces the history of several novel theranostic agents developed from compassionate N-of-One studies by hospital physicians over the past 36 years. It acknowledges the collegiality and collaboration of individual nuclear medicine specialists, worldwide, in pioneering effective humane therapy of particular advanced cancers unresponsive to conventional treatments.","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"323-329"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139698976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re: "Evaluating the Diagnostic Efficacy of ^99mTc-Methionine Single-Photon Emission Computed Tomography-Computed Tomography: A Head-to-Head Comparison with ¹¹C-Methionine Positron Emission Tomography-Magnetic Resonance Imaging in Glioma Patients" by Kumar et al. 关于"评估 99mTc 蛋氨酸单光子发射计算机断层扫描的诊断功效：与 11C-Methionine 正电子发射计算机断层扫描-磁共振成像在胶质瘤患者中的头对头比较"，作者 Kumar 等。

IF 2.4 4区医学

Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-06-01 Epub Date: 2024-03-14 DOI: 10.1089/cbr.2024.0023

Luca Filippi

引用次数: 0

The Role of [¹⁸F]FDG PET/CT in the Characterization of Thymic Epithelial Tumors at Initial Stage. 18F]FDG PET/CT 在初期胸腺上皮肿瘤特征描述中的作用

IF 2.4 4区医学

Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-06-01 Epub Date: 2024-03-14 DOI: 10.1089/cbr.2023.0192

Caner Civan, Zeynep Gozde Ozkan, Berker Ozkan, Emine Goknur Isik, Eren Erdogdu, Duygu Has Simsek, Salih Duman, Yasemin Sanli, Murat Kara, Serkan Kuyumcu, Alper Toker

{"title":"The Role of [18F]FDG PET/CT in the Characterization of Thymic Epithelial Tumors at Initial Stage.","authors":"Caner Civan, Zeynep Gozde Ozkan, Berker Ozkan, Emine Goknur Isik, Eren Erdogdu, Duygu Has Simsek, Salih Duman, Yasemin Sanli, Murat Kara, Serkan Kuyumcu, Alper Toker","doi":"10.1089/cbr.2023.0192","DOIUrl":"10.1089/cbr.2023.0192","url":null,"abstract":"Purpose: The aim of this study was to evaluate the potential role of [18F]FDG positron emission tomography/computed tomography (PET/CT) in the characterization of thymic epithelial tumors (TETs). Materials and Methods: A total of 73 patients who underwent preoperative [18F]FDG PET/CT were included in this study. Visual total score (VTS), maximum standard uptake values (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and heterogeneity index (HI) parameters were analyzed to investigate the prediction of histopathologic grade and advanced stage. Results: The cohort included 26 patients with low-grade thymoma (LGT), 36 patients with high-grade thymoma (HGT), and 11 patients with thymic carcinoma (TC). Ninety-one percent of TC had VTS >2, whereas 31% of LGT and 75% of HGT had VTS >2. SUVmax, MTV, and TLG were statistically significantly higher in the TC group than in both thymoma and HGT. Using the cutoff value of 7.25 for SUVmax, TC was differentiated from thymomas with 91% sensitivity and 74% specificity. TC had significantly lower HI values than thymomas. HI parameters showed good diagnostic ability to differentiate TC from thymoma and TC from HGT. SUVmax, MTV, and TLG were significantly higher in advanced-stage disease than in early-stage disease. Conclusions: Visual and quantitative parameters can reliably predict both advanced disease and the grade of primary tumor in TETs. Therefore, as a promising metabolic imaging method, [18F]FDG PET/CT makes important contributions to preoperative evaluation in routine clinical practice.","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"373-380"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of Early Versus Delayed Hepatic Artery Perfusion Scan on ⁹⁰Y Selective Internal Radiation Therapy Planning. 早期肝动脉灌注扫描与延迟肝动脉灌注扫描对 90Y 选择性内放射治疗计划的影响

IF 2.4 4区医学

Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-06-01 Epub Date: 2024-01-24 DOI: 10.1089/cbr.2023.0149

Bilal Kovan, Dilara Denizmen, Caner Civan, Serkan Kuyumcu, Emine Goknur Isik, Duygu Has Simsek, Zeynep Gozde Ozkan, Arzu Poyanli, Bayram Demir, Yasemin Sanli

{"title":"Influence of Early Versus Delayed Hepatic Artery Perfusion Scan on 90Y Selective Internal Radiation Therapy Planning.","authors":"Bilal Kovan, Dilara Denizmen, Caner Civan, Serkan Kuyumcu, Emine Goknur Isik, Duygu Has Simsek, Zeynep Gozde Ozkan, Arzu Poyanli, Bayram Demir, Yasemin Sanli","doi":"10.1089/cbr.2023.0149","DOIUrl":"10.1089/cbr.2023.0149","url":null,"abstract":"Purpose: This study evaluated the effect of an increase in the time interval between hepatic intra-arterial injection of 99mTc-macroaggregated albumin (MAA) and hepatic artery perfusion scintigraphy (HAPS) on the lung shunt fraction (LSF) and perfused volume (PV) calculations in the treatment planning of selective internal radiation therapy (SIRT). Methods: The authors enrolled 51 HAPS sessions from 40 patients diagnosed with primary or metastatic liver malignancy. All patients underwent scan at the first and fourth hour after hepatic arterial injection of 99mTc-MAA. Based on single-photon emission computed tomography images, LSF values were measured from each patient's first and fourth hour images. PV1 and PV4 were also calculated based on three-dimensional images using 5% and 10% cutoff threshold values and compared with each other. Results: The authors found that the median of LSF4 was statistically significantly higher than LSF1 (3.05 vs. 4.14, p ≤ 0.01). There was no statistically significant difference between PV1 and PV4 on the 10% (p = 0.72) thresholds. Conclusions: LSF values can be overestimated in case of delayed HAPS, potentially leading to treatment cancellation due to incorrectly high results in patients who could benefit from SIRT. Threshold-based PV values do not significantly change over time; nevertheless, keeping the short interval time would be safer.","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"330-336"},"PeriodicalIF":2.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139543981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of DNA/RNA Deregulation in Cancer Using ^99mTc-Labeled Thiopurine. 使用 99mTc 标记的硫嘌呤评估癌症中的 DNA/RNA 失调。

IF 2.4 4区医学

Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-06-01 Epub Date: 2024-03-08 DOI: 10.1089/cbr.2023.0148

Chuang-Hsin Chiu, David J Yang, Yi-Chen Liou, Wei-Chung Chang, Tsung-Hsun Yu, Min-Ching Chung, Yen-Chun Lee, Ing-Jou Chen, Pao-Yeh Wang, Ching-Po Lin, Hey-Jen Tsay, Skye Hsin-Hsien Yeh

引用次数: 0

Radiotherapy and Anrotinib in Malignant Glomus Tumor of the Bladder: A Case Report and Literature Review. 放疗和安罗替尼治疗恶性膀胱结节瘤：病例报告与文献综述

IF 3.4 4区医学

Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-05-01 Epub Date: 2024-02-07 DOI: 10.1089/cbr.2023.0151

Jing Ai, Shuang Zhang, Yimeng Qian, Lin Kang, Litao Zhang, Jing Zhao

引用次数: 0

A Prognostic Model for Prostate Cancer Patients Based on Two DNA Damage Response Mutation-Related Immune Genes. 基于两个 DNA 损伤反应突变相关免疫基因的前列腺癌患者预后模型

IF 3.4 4区医学

Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-05-01 Epub Date: 2023-08-22 DOI: 10.1089/cbr.2023.0033

Jian Wang, Li Jiang, Zhenhua Shang, Zhaohua Ye, Dan Yuan, Xin Cui

{"title":"A Prognostic Model for Prostate Cancer Patients Based on Two DNA Damage Response Mutation-Related Immune Genes.","authors":"Jian Wang, Li Jiang, Zhenhua Shang, Zhaohua Ye, Dan Yuan, Xin Cui","doi":"10.1089/cbr.2023.0033","DOIUrl":"10.1089/cbr.2023.0033","url":null,"abstract":"Background: DNA damage response (DDR) mutation-related genes and composition of immune cells are core factors affecting the effectiveness of immune checkpoint inhibitor therapy. The aim of this study is to combine DDR with immune-related genes to screen the prognostic signature for prostate cancer (PCa). Methods: Gene expression profile and somatic mutation were downloaded from The Cancer Genome Atlas (TCGA). DDR-related genes were obtained from published study. After identification of prognostic-related DDR genes, samples were divided into mutation and nonmutation groups. Differentially expressed genes between these two groups were screened, followed by selection of immune-related DDR genes. Univariate and multivariate Cox analyses were performed to screen genes for constructing prognostic model. Nomogram model was also developed. The expression level of signature was detected by quantitative real-time PCR (qPCR). Results: Two genes (MYBBP1A and PCDHA9) were screened to construct the prognostic model, and it showed good risk prediction of PCa prognosis. Survival analysis showed that patients in high-risk group had worse overall survival than those in low-risk group. Cox analyses indicated that risk score could be used as an independent prognostic factor for PCa. qPCR results indicated that MYBBP1A was upregulated, whereas PCDHA9 was downregulated in PCa cell lines. Conclusions: A prognostic model based on DDR mutation-related genes for PCa was established, which serves as an effective tool for prognostic differentiation in patients with PCa.","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"306-317"},"PeriodicalIF":3.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10414408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LncRNA SNHG6 Promotes Wilms' Tumor Progression Through Regulating miR-429/FRS2 Axis. LncRNA SNHG6通过调控miR-429/FRS2轴促进Wilms'肿瘤进展

IF 3.4 4区医学

Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-05-01 Epub Date: 2021-01-22 DOI: 10.1089/cbr.2020.3705

Yingjie Wang, Junli Liu, Qiying Yao, Yuchuan Wang, Zhengjuan Liu, Li Zhang

{"title":"LncRNA SNHG6 Promotes Wilms' Tumor Progression Through Regulating miR-429/FRS2 Axis.","authors":"Yingjie Wang, Junli Liu, Qiying Yao, Yuchuan Wang, Zhengjuan Liu, Li Zhang","doi":"10.1089/cbr.2020.3705","DOIUrl":"10.1089/cbr.2020.3705","url":null,"abstract":"Background: Long noncoding RNA (lncRNA) small nucleolar RNA host gene 6 (SNHG6) has been reported to be an oncogene in a variety of cancers. However, the role of SNHG6 and its associated mechanisms in Wilms' tumor progression remain largely unknown. Methods: The expression of SNHG6, microRNA-429 (miR-429), and FGF receptor substrates 2 (FRS2) messenger RNA (mRNA) was detected by quantitative real-time polymerase chain reaction. Cell proliferation was analyzed through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and plate colony assay. The apoptosis was assessed by flow cytometry. Cell glycolytic metabolism was analyzed through detecting the lactate dehydrogenase activity, glucose uptake, lactate production, and ATP level. The target relationship between miR-429 and SNHG6 or FRS2 was predicted by miRcode or Starbase and then validated by dual-luciferase reporter assay and RNA pull-down assay. Murine xenograft model was established to validate the function of SNHG6 in vivo. Results: The level of SNHG6 was elevated in Wilms' tumor tissues and cells, and SNHG6 played an oncogenic role to promote the proliferation and glycolysis and restrain the apoptosis of Wilms' tumor cells. MiR-429 was identified as a target of SNHG6, and miR-429 interference partly reversed the inhibitory effects induced by SNHG6 silencing on the malignant behaviors of Wilms' tumor cells. FRS2 mRNA bound to miR-429 in Wilms' tumor cells. SNHG6 upregulated the expression of FRS2 through acting as a sponge of miR-429. MiR-429-induced influences in Wilms' tumor cells were largely counteracted by the overexpression of FRS2. SNHG6 silencing suppressed the Wilms' tumor growth through miR-429/FRS2 axis in vivo. Conclusion: SNHG6 accelerated Wilms' tumor progression through regulating miR-429/FRS2 signaling in vitro and in vivo.","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"264-275"},"PeriodicalIF":3.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38852930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Promising Therapeutic Targets in Kidney Renal Clear Cell Carcinoma: PLXNA1 and PLXNB3. 肾脏透明细胞癌的有望治疗靶点：PLXNA1 和 PLXNB3。

IF 3.4 4区医学

Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-05-01 Epub Date: 2021-12-01 DOI: 10.1089/cbr.2021.0336

Can-Xuan Li, Dan Long, Quan Meng

引用次数: 0